Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer

被引:58
作者
Sekine, Katsutoshi [1 ,2 ]
Kanda, Shintaro [1 ]
Goto, Yasushi [1 ]
Horinouchi, Hidehito [1 ]
Fujiwara, Yutaka [1 ]
Yamamoto, Noboru [1 ]
Motoi, Noriko [3 ,4 ]
Ohe, Yuichiro [1 ]
机构
[1] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[2] Saitama Municipal Hosp, Dept Internal Med, Saitama, Japan
[3] Natl Canc Ctr, Dept Pathol, Tokyo, Japan
[4] Natl Canc Ctr, Dept Clin Labs, Tokyo, Japan
关键词
Nivolumab; Non-small-cell lung cancer (NSCLC); Lymphocyte-to-monocyte ratio (LMR); Neutrophil-to-lymphocyte ratio (NLR); PLATINUM-BASED CHEMOTHERAPY; PRETREATMENT NEUTROPHIL; PROGNOSTIC-SIGNIFICANCE; PERIPHERAL-BLOOD; ADVERSE EVENTS; PD-1; BLOCKADE; STAGE IV; MELANOMA; THERAPY; PEMBROLIZUMAB;
D O I
10.1016/j.lungcan.2018.08.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Nivolumab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, has been shown to yield a durable response and significant prolongation of the survival in some patients with non-small-cell lung cancer (NSCLC). However, identification of patients who are likely to respond to nivolumab remains difficult at present. Materials and methods: We conducted a retrospective analysis of the clinical data of 87 consecutive patients with advanced NSCLC seen in clinical practice who received nivolumab monotherapy at the National Cancer Center Hospital in Japan between January 2016 and July 2016 (discovery cohort). In addition, we also collected the clinical data of 75 patients who were administered nivolumab monotherapy between August 2016 and March 2017 (validation cohort). For this study, we focused on the changes in the lymphocyte-to-monocyte ratio (LMR) observed after nivolumab monotherapy. Results: In the discovery cohort, increase ( >= 10%) of the LMR at 4 weeks after the start of nivolumab monotherapy relative to the pretreatment LMR was positively correlated with an objective response (objective response rate (ORR); 39.4% vs 11.8%, p = 0.0065). When this cutoff value of >= 10% was used, increase of the LMR was significantly associated with a prolonged progression-free survival (PFS) (median PFS [mPFS]; 7.3 months vs 2.5 months, p = 0.0049) and overall survival (OS) (median survival time; 15.6 months vs 8.9 months, p = 0.014). In the validation cohort also, increase of the LMR was significantly associated with higher ORR (50.0% vs 20.0%, p = 0.015) and prolonged PFS (mPFS; not reached vs 3.1 months, p = 0.0092). On the other hand, no such correlation was observed among patients treated with docetaxel. Conclusion: A rapid increase of the LMR was significantly associated with the effects of nivolumab monotherapy in our study cohort. Therefore, early change of the LMR may be used as a novel effective surrogate marker to decide on continuation of anti-PD-1 therapy.
引用
收藏
页码:179 / 188
页数:10
相关论文
共 30 条
  • [1] Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
    Bagley, Stephen J.
    Kothari, Shawn
    Aggarwal, Charu
    Bauml, Joshua M.
    Alley, Evan W.
    Evans, Tracey L.
    Kosteva, John A.
    Ciunci, Christine A.
    Gabriel, Peter E.
    Thompson, Jeffrey C.
    Stonehouse-Lee, Susan
    Sherry, Victoria E.
    Gilbert, Elizabeth
    Eaby-Sandy, Beth
    Mutale, Faith
    DiLullo, Gloria
    Cohen, Roger B.
    Vachani, Anil
    Langer, Corey J.
    [J]. LUNG CANCER, 2017, 106 : 1 - 7
  • [2] Neutrophil to lymphocyte ratio associated with prognosis of lung cancer
    Bar-Ad, V.
    Palmer, J.
    Li, L.
    Lai, Y.
    Lu, B.
    Myers, R. E.
    Ye, Z.
    Axelrod, R.
    Johnson, J. M.
    Werner-Wasik, M.
    Cowan, S. W.
    Evans, N. R.
    Hehn, B. T.
    Solomides, C. C.
    Wang, C.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (06) : 711 - 717
  • [3] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [4] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
    Brahmer, Julie
    Reckamp, Karen L.
    Baas, Paul
    Crino, Lucio
    Eberhardt, Wilfried E. E.
    Poddubskaya, Elena
    Antonia, Scott
    Pluzanski, Adam
    Vokes, Everett E.
    Holgado, Esther
    Waterhouse, David
    Ready, Neal
    Gainor, Justin
    Aren Frontera, Osvaldo
    Havel, Libor
    Steins, Martin
    Garassino, Marina C.
    Aerts, Joachim G.
    Domine, Manuel
    Paz-Ares, Luis
    Reck, Martin
    Baudelet, Christine
    Harbison, Christopher T.
    Lestini, Brian
    Spigel, David R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) : 123 - 135
  • [5] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
    Carbone, D. P.
    Reck, M.
    Paz-Ares, L.
    Creelan, B.
    Horn, L.
    Steins, M.
    Felip, E.
    van den Heuvel, M. M.
    Ciuleanu, T. -E.
    Badin, F.
    Ready, N.
    Hiltermann, T. J. N.
    Nair, S.
    Juergens, R.
    Peters, S.
    Minenza, E.
    Wrangle, J. M.
    Rodriguez-Abreu, D.
    Borghaei, H.
    Blumenschein, G. R.
    Villaruz, L. C.
    Havel, L.
    Krejci, J.
    Corral Jaime, J.
    Chang, H.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Chen, A. C.
    Socinski, M. A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) : 2415 - 2426
  • [6] Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer
    Cedres, S.
    Torrejon, D.
    Martinez, A.
    Martinez, P.
    Navarro, A.
    Zamora, E.
    Mulet-Margalef, N.
    Felip, E.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (11) : 864 - 869
  • [7] Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Chen, Yu-Mu
    Lai, Chien-Hao
    Chang, Huang-Chih
    Chao, Tung-Ying
    Tseng, Chia-Cheng
    Fang, Wen-Feng
    Wang, Chin-Chou
    Chung, Yu-Hsiu
    Wang, Yi-Hsi
    Su, Mao-Chang
    Huang, Kuo-Tung
    Chen, Hung-Chen
    Chang, Ya-Chun
    Lin, Meng-Chih
    [J]. PLOS ONE, 2015, 10 (08):
  • [8] Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
    Diem, Stefan
    Schmid, Sabine
    Krapf, Mirjam
    Flatz, Lukas
    Born, Diana
    Jochum, Wolfram
    Templeton, Arnoud J.
    Fruh, Martin
    [J]. LUNG CANCER, 2017, 111 : 176 - 181
  • [9] Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
    Garon, Edward B.
    Rizvi, Naiyer A.
    Hui, Rina
    Leighl, Natasha
    Balmanoukian, Ani S.
    Eder, Joseph Paul
    Patnaik, Amita
    Aggarwal, Charu
    Gubens, Matthew
    Horn, Leora
    Carcereny, Enric
    Ahn, Myung-Ju
    Felip, Enriqueta
    Lee, Jong-Seok
    Hellmann, Matthew D.
    Hamid, Omid
    Goldman, Jonathan W.
    Soria, Jean-Charles
    Dolled-Filhart, Marisa
    Rutledge, Ruth Z.
    Zhang, Jin
    Lunceford, Jared K.
    Rangwala, Reshma
    Lubiniecki, Gregory M.
    Roach, Charlotte
    Emancipator, Kenneth
    Gandhi, Leena
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) : 2018 - 2028
  • [10] Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
    Gros, Alena
    Parkhurst, Maria R.
    Tran, Eric
    Pasetto, Anna
    Robbins, Paul F.
    Ilyas, Sadia
    Prickett, Todd D.
    Gartner, Jared J.
    Crystal, Jessica S.
    Roberts, Ilana M.
    Trebska-McGowan, Kasia
    Wunderlich, John R.
    Yang, James C.
    Rosenberg, Steven A.
    [J]. NATURE MEDICINE, 2016, 22 (04) : 433 - +